<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949089</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-PSD-01(04/11)</org_study_id>
    <nct_id>NCT02949089</nct_id>
  </id_info>
  <brief_title>ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects</brief_title>
  <official_title>An Open Label, Dose Escalation Study of ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to provide information on the safety and tolerability of repeated oral
      doses of ACH04. A phase I, single-center, first in human, open-label, dose escalation study
      of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best
      address the study goals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety of rising multiple doses of ACH04</measure>
    <time_frame>up to 39 days</time_frame>
    <description>Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>ACH04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage: 1 capsule, PO, 24/24h for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH04</intervention_name>
    <description>The subjects will receive the study medication in each group</description>
    <arm_group_label>ACH04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be healthy males subjects between 18 and 50 years of age;

          -  Subjects must be in good healthy as determined by a medical history, physical
             examination and clinical laboratory evaluations;

          -  Subjects will, prior to any study related activities, have given their written
             informed consent to participate in the study and to abide by the stdy restrictions.

        Exclusion Criteria:

          -  Subjects with hypersensitivity known to Psidium guajava L. or history of serious
             adverse events;

          -  Subjects who have a significant history of alcoholism or drug/chemical abuse;

          -  Subjects who have body mass index &lt; 18 or &gt; 30;

          -  Subjects who have received any medications that is known to have a toxic potential
             well defined in large organs within the past 3 months prior the study start;

          -  Subjets who doesn´t agree to use, for the duration of the study, a barrier
             contraceptive;

          -  Subjects who were hospitalized for any reason in the six week prior the study start;

          -  Subjects who, in the opinion of the investigator, should not participate in the study,
             including subjects suspected for whatever reason of not being able to comply with the
             requirements of the protocol;

          -  Subjects who are participating in a clinical trial or have participated in a clinical
             study involving administration of an investigational drug, within one year;

          -  Subjects who are relatives of employees from the sponsor and the site, respectively;

          -  Subjects with, or with a history of, any clinically significant neurological,
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,
             endocrine, haematological, dermatological or other major disorders as determined by
             the Investigator;

          -  Any finding of clinical observation (anamnesis and physical evaluation), laboratory
             abnormality, who in the investigator opinion, may jeopardize the subjects or interfere
             with the study goals.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UNIFAC</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60160140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>rising multiple doses</keyword>
  <keyword>ACH04</keyword>
  <keyword>adult</keyword>
  <keyword>male</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

